AKAP12

Across TCGA pan-cancer cohorts, AKAP12 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AKAP12 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AKAP12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AKAP12 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where AKAP12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.544	0.297	.021	13	view →
LUAD	DFS	Median	All	0.737	0.508	.010	9	view →
UCEC	OS	Median	II,III,IV	0.647	1.000	.017	8	view →
LSCC	OS	Median	II,III,IV	0.903	1.000	.017	5	view →
CCRCC	DFS	Quartile	III,IV	0.887	0.531	.036	2	view →
HNSC	OS	Quartile	II,III,IV	0.925	1.000	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AKAP12–PDAC (DFS)

Open the PDAC breakdown →